Balloon for drug elution instrument and drug elution instrument

Abstract

The invention relates to the field of medical apparatuses and instruments, in particular to a balloon for a drug elution instrument and the drug elution instrument; the drug elution instrument comprises the balloon for the drug elution instrument, an inner tube and an outer tube; the balloon for the drug elution instrument comprises a balloon body and a balloon binding wire; the balloon binding wire is arranged on the surface of the balloon body; the balloon body extends axially; the balloon binding wire is parallel to the axial direction of the balloon body or at least part of the balloon binding wire is obliquely crossed with the axial direction of the balloon body; the balloon body or the balloon binding wire is made of an elastic material; the elastic modulus of the balloon binding wire is higher than that of the balloon body; the inner tube is arranged on the balloon body in a penetrating mode; furthermore, one end of the balloon body is fixedly connected with the inner tube; the outer tube is arranged on part of the inner tube in a sleeving mode; and the other end of the balloon body is connected with the outer tube. The drug elution instrument disclosed by the invention can reduce drug loss during delivery, realizes rapid transfer at a focus, and does not need to be inflated and deflated frequently during delivery.

Description

technical field [0001] The invention relates to the field of medical devices, in particular to a balloon for drug eluting devices and a drug eluting device. Background technique [0002] Cardiovascular and cerebrovascular diseases are a class of diseases with a high mortality rate. With the improvement of people's material level, the acceleration of the pace of life and the change of lifestyle, the incidence and mortality of cardiovascular and cerebrovascular diseases are increasing and younger. At present, cardiovascular and cerebrovascular diseases are mainly coronary heart disease, atherosclerosis, cerebral infarction and malignant tumors and cancers. [0003] For such diseases, Dotter and his colleagues proposed the concept of percutaneous transluminal angioplasty in 1964. The development of percutaneous transluminal angioplasty has experienced from percutaneous transluminal angioplasty (PCI) to bare metal stent placement. The development process from BMS to drug-eluti...

AI Technical Summary

Problems solved by technology

However, DCB also has some disadvantages. Since DCB continues to receive perfusion of blood flow in the blood vessel when it enters the body, the drug-loaded layer on the surface of the balloon is prone to loss under the action of perfusion. The expanded balloon will be filled with blood vessels. In order not to block blood vessels for a long time and cause necrosis of body cells and tissues, the expansion time of DCB is generally limited to within 60 seconds, and then the balloon needs to be deflated and then inflated again, which makes the drug-loaded layer from the balloon When the surface of the capsule is transferred to the lesion for many times, the drug loss is relatively large, which greatly affects the therapeutic effect of DCB

Images